Anaemia - PowerPoint PPT Presentation

1 / 98
About This Presentation
Title:

Anaemia

Description:

PowerPoint Presentation ... Anaemia – PowerPoint PPT presentation

Number of Views:391
Avg rating:3.0/5.0
Slides: 99
Provided by: KOZ96
Category:

less

Transcript and Presenter's Notes

Title: Anaemia


1
Anaemia

2
  • Anaemia from greek meaning lack of blood
  • Anaemia less than the normal quantity of
    hemoglobin in the blood
  • Anaemic syndrome clinical syndrome caused by
    tissue hypoxia

3
NORMAL VALUES OF RED BLOOD CELLS
men
women Haemoglobin (Hb) 136
176 120 - 168 g/l Haematocrite
(HTK) 0,38 0,49 0,35 0,46 No of
erythrocytes (RBC) 4,2 5,8 3,8
5,2 x1012/l Volume of erythrocyte (MCV) 80
95 fl Mass of Hb in erythrocyte 26 32
pg (MCH) Hb concentration in
erythrocyte 0,32 0,37
(MCHC)
4
NORMAL VALUES OF RED BLOOD CELLS

men
women Haemoglobin (Hb) 136
176 120 - 168 g/l Haematocrite
(HTK) 0,38 0,49 0,35 0,46 No of
erythrocytes (RBC) 4,2 5,8 3,8 5,2
x1012/l Volume of erythrocyte (MCV) 80 95
fl Mass of Hb in erythrocyte 26 32
pg (MCH) Concentration of Hb in
erythrocyte 0,32 0,37
(MCHC)
5
Anaemic syndrome - symptomsrom (AS)
  • Tissue hypoxia pallor, fatigue, weakness,
    dyspnea
  • Compensation and adaptation
  • Hypercinetic circulation, palpitations, tinnitus
  • Secondary
  • Cardiovascular symptoms decompensation of
    ischemic heart disease, AP, IM, claudications

6
Anemický syndrom (AS)
  • Progress and severity of AS depends on
  • 1. Absolute value of Hb
  • Hgb 70-80 g/l most of patients suffer from
    symptoms
  • 2. Speed of onset
  • 3. Age and overall performance of the patient

7

8
  • IRON PROTOPORFYRIN
  • HAEM GLOBIN

  • HAEMOGLOBIN

DNA B12 ,folic acid, EPO
9
ANAEMIA - CLASSIFICATION
  • Morfologic criteria
  • According to MCV (80 95 fl)
  • microcytic, normocytic, macrocytic
  • According to MCH (27-32 pg)
  • normochrome, hypochrome
  • According to no of reticulocytes (0,7 2,8 )
  • anaemia with lowered, normal or incresed no
    of reticulocytes

10
  • MICROCYTIC ANAEMIA
  • Iron deficiency anaemia
  • Chronic disease anaemia
  • Thalasemia, sideroblastic anaemia
  • MACROCYTIC ANAEMIA
  • Megaloblaste anaemia(lack of B12, folic acid,
    MDS)
  • Macrocytic non-megaloblaste anaemia (usually
    secondary)
  • NORMOCYTIC ANAEMIA
  • Primar impairment of blood marrow aplastic
    anaemia, MDS, PNH,
  • myelofibrosis.
  • Secondary impairment of blood marrow
    (infiltration, infection,
  • endocrinological and systemic diseases,
    ACD)
  • D. ANAEMIA WITH RETICULOSIS
  • Haemolytic aneamia corpuscular
  • Haemolytic anaemia extracorpuscular
  • imunne and non-immune based

11
Pathofysiological classification

12

EPO
13

EPO
TSH
Fe, Fol, B12
C, E
14

15

16

17
Pathofysiological classification
  • Proliferation and differentiation disorder
  • Increased destruction of RBC
  • Blood loss
  • Combined etiology

18
  • IRON
    PROTOPORFYRIN
  • Iron insufficiency
    sideroblastic anaemia
  • ACD
  • HEM GLOBIN

  • thalasemia
  • HEMOGLOBIN

DNA B12, folic acid, EPO
19
Iron defficiency

20
Iron defficiency
  • Most frequent cause of anemia
  • (500 000 000 worldwide WHO)
  • 80of all anaemia
  • SA 10 of fertile women
  • Sideropenia 35-58 of fertile women

21
Iron defficiency CAVE influencing not just the
blod count!
  • DNA synthesis impairement
  • Tissue fosforylation impairement
  • Purine metabolism impairement
  • Colagen synthesis impairement
  • Granulocyte function impairement
  • Neurotransmiter function impairement

22

Iron distribution in the organism

23

24

25
Iron metabolism
  • Food contents 15-20mg/den
  • Absorption 1-2mg (duodenum, upper part of
    jejunum)
  • Loss (epitel desqvamation) 1-2mg
  • Pregnancy overall loss 500-1000mg
  • Supply in the organism 3000-5000mg

26
Hepcidine
  • Acute phase reactant
  • Source hepatic cells, heart,
  • Iron stimulates Hepcidine
  • Hepcidine inhibits iron absorption in the
    intestine, iron release from macrophages and iron
    transport via placenta
  • ACD, hereditary hemochromatosis

27
Iron defficiency
  • Insufficient intake - malnutrition
  • Absorption impairement
  • maldigestion, malabsorption
  • Increased loss
  • Lowered intake

28
Insufficient intake
  • Malnutrition
  • Imbalanced diet
  • Vegetarians
  • - Meat 25-30 of iron is absorbed
  • - Vegetables 5 of iron is absorbed

29

Iron absorption from various foods ()
Rice Spinach Beans Corn Lettuce Wheat Soya Ferriti
n Veal liver Fish meat Haemoglobin Veal meat

30

Iron absorption from
various foods ()
Rice Spinach Beans Corn Lettuce Wheat Soya
beans Ferritin Veal liver Fish meat Haemoglobin Ve
al meat

31
Absorption disorder
  • Resection of stomach 65 patients
  • Achlorhydria
  • Coeliakia
  • M. Crohn
  • Infection H. Pylori with gastritis

32
Loss
  • GIT (h. hernia, gastritis, ulcerous disease,
    tumours, intestinal inflammmatory diseases,
    hemorhoids, parasites, diverticulitis)
  • Respiratory tractus
  • Urogenital tract
  • Menses cca 3mg Fe / den
  • NSAIDs, hemodialysis, blood testing, self -
    harming

33
Increased need
  • Gravidity
  • Brest-feeding
  • Growth

34
Symptoms
  • Anemic syndrome
  • Cefalea, paresthesia, fatigue
  • Tongue burning, angulitis
  • Odyno-, dysfagia
  • Sy Kelly-Patterson
  • Brittle hair, nails
  • (Pica, pagofagia)

35
Physical examination
  • Pallor skin, mucous membrane
  • Blue sclerae
  • Ulcers/ angulitis
  • Smooth tongue
  • Straight/(spoon-shaped) nails
  • Achlorhydria, atrophic gastritis

36
Laboratory findings
  • RDW high
  • Trombocytosis (over 50 of patients)
  • BM staining for iron
  • - lack of Fe in siderophages
  • - sideroblasts lower then 10

37
Laboratory findings
  • MCV under 80fl
  • MCH under 25ug
  • MCHC late symptom
  • Transferrin -increased
  • S-ferritin lt20ug/l
  • Transferrin satur. under15 (N 20-40)
  • VKFe (TIBC) increased
  • S-sTfR gt 8g/l

38
DIFFERENTIAL DIAGNOSIS OF IRON INSUFFICIENCY
(mikrocytic anaemia)

Fe TIBC satTRF ferritin TRF

receptor
_______________________________________________ 
Iron insuf. ? ? ?
? ?     Chronic disease
associated anaemia ? ?
N N N
(ACD)     Thalasemia N or ? N or ? N
or ? N or ? ?    
39
CAVE
  • Ferritine
  • Acute phase reactant
  • Nespecific tumorous marker
  • Level increases with age
  • (75ug/l in old people ? iron defficiency)

40
Iron defficiency
  • Prelatent
  • Latent
  • Manifest - SA

41
Typical patient with IDA
  • Woman 20-45y, fatigue, sleepiness, ear buzzing,
    hairloss, brittle nails, hyper- polymenorhea or
    normal menses.
  • 2. Man 50y or older, dysfagia, weightloss,
    treated with ASA for ICD, blood in stools or
    urine.

42
Treatment of IDA
  • Treatment of the cause of iron loss
  • iron supply

43

44
Ferrotherapy
  • 150-200mg Fe / day
  • Until enough supply is formed (ferritin 50ug/l)
  • Use on an empty stomach
  • CAVE polyphenols, milk, egg yolk
  • Dyspepsia
  • Parenteral forms (CAVE anaphylaxis x new forms
    are safer - karboxymaltose)

45

Ferinject (Vifor, Francie)
inj. Fe3 karboxymaltóza
100mg, 500mg
46
P.o. iron treatment control
  • Reticulocyte crisis D 10-14
  • Increase of haemoglobin
  • Normalisation of MCV a RDW
  • Iron supply forming
  • Ineffective treatment
  • Diagnosis checking BM examination, GIT
    examination aso. Cave self-harming
  • Switch to i.v. therapy

47
Thalassemia

48
  • IRON PROTOPORFYRIN
  • Fe insufficiency
    sideroblastic anemia
  • ACD
  • HEM GLOBIN


  • thalasemia
  • HEMOGLOBIN

DNA B12 , folic acid
49
Thalassemia
  • thalasemia, 0thalasemia
  • Fetus - Hb F a2 ?2
  • Adult - Hgb A a2 ß2
  • - Hgb A2 a2 d2
  • - Hgb F a2 ?2

50
Thalassemia
  • a thalasemia a disorder
  • ß thalasemia ß disorder

51
a - Thalassemia
  • (Normal genotype a a / a a)
  • - a/ a a silent carrier
  • - a/- a , - - / a a carrier (mikrocytosis,
    erythrocytosis)

  • Thalassemia minor
  • - - / - a HbH (ß4) (splenomegalia,
    mikrocytosis, bones)
  • - - / - - hydrops fetalis, sy Hb Barts (?4)

52
ß - Thalassemia
  • More severe then athalassemia
  • ß thalasemia minor (ß/ ß, ß0/ ß)
  • Mikrocytosis, anaemia, erythrocytosis
  • ß thalasemia intermedia (ß/ ß, ß0/ ß)
  • ß thalasemia major (ß0/ ß0, ß/ ß)
  • Severe anemia, anisopoikilocytosis, affected
    ERY, HbF, hepatosplenomegalia,bone
    deformities,permanent transfusion therapy, Fe
    overload, Tx, splenectomia, HU

53
BETA THALASEMIA
  • Pathogenesis
  • ? chains formation impairement ? increased
    synthesis of ? and ?
  • Alpha chains overdose low solubility,
    precipitation, agregates deform cell membranes
  • Hb easy autooxidation, lower stability ?
    release of
  • Fe ? cell destruction by peroxidative
    lipid cleavage.
  • Inefective erythropoiesis, large numbers of
    erytrocytes decline as soon as the BM
    peripheral hemolysis shortened lifespan
  • Significant compensatory erythropoiesis
    hyperplasia?
  • corticalis usuration?bone deformities,
    fractures, extramedular
  • hemopoiesis
  • Relative Fe defficiency in BM because of
    hyperplastic
  • erythropoiesis, at the same time increased
    Fe supply (coming from destroyed ery in monocyte-
    macrophage system) ? increased Fe resorption in
    the intestine? Fe overload of the organism
    (together with Fe coming from transfusions).

54

55

56
MEGALOBLASTIC ANAEMIA
  • Lack of B12of folic acid
  • 1. Pernicious anaemia - B12 absorption in the
    distal intestine disorder due to lack of
    intrinsic factor (produced by parietal cells of
    gastric mucosa)
  • 2. Dihydrofolat reductase inhibitors (MTX,
    ARA-C)

57
MEGALOBLASTIC ANAEMIA -CAUSES
  • Insufficient intake of B12 of folic
  • Absorption impairement
  • a) lack of intrinsic factor, intrinsic
    factor
  • b) celiakia, Crohn disease, intestinal
    resection, diverticules, strictures,parasites
  • c) resorption inhibitors (fenylhydantoin,PAS
    ,pyrimidin, neomycin)
  • d) selective malabsorption B12 with
    proteinuria
  • Transport disorders because of lack of
    transkobalamin I. and II.
  • Increased demand (gravidity, growth, anaemia with
    hyperplasia of erythropoiesis
  • Increased loss (hepatic laesions, bleeding)
  • dihydrofolat reductase inhibitors
    (MTX,pyrimethamin)
  • pyrimidin antagonists (ARA-C) / purin
    antagonists (6-MP)

58
Megaloblastic anaemia
  • Blood count macrocytes (?MCV, ?MCH,normal
  • MCHC), ?RTC, megalocytes, megaloblasts,
  • leukocytosis with left shift,
    thrombocytopenia.
  • Bone marrow hyperplasia of erytropoiesis,
    megaloblasts,
  • granulocyte macrocytosis, mgkc. polyploidia
  • dif.dg. MDS (cytogenetics, cytochemistry)
  • biochemistry ? B12, ?folic acid, ?direct and
    indirect
  • bilirubin, intrinsic factor antibodies,
    antibodies against parietal cells, normal iron
    supplies

59
(No Transcript)
60
Proteins binding VITAMIN B12 Intrinsic
factor B12 absorption in ileum, binding to
specific receptor (cubilin) Secerned by parietal
gastric cells In case of lack leads to B12
malabsorption TRANSCOBALAMIN I Binds B12 in
plasma,binds to B12 in stomach before binding to
intrinsic factor, produced by neutrofiles and
cells with exocrine secretion, his lack leads to
low serum B12 levels TRANSCOBALAMIN II Enables
B12 absorption by cells, receptor on all type of
cells, produced by endotelial cells, fibroblasts,
ileum cells.., his lack leads to severe B12
deficiency in cells
61
(No Transcript)
62
Pernicious anaemia
63
Megaloblastic anaemiaDiferential dg.
  • atrofic gastritis / sprue/ inflamations,
    parasites/ medication/ liver laesions
  • DNA synthesis impairement due to abnormal cell
    clone MDS
  • (bone marrow biopsy,
  • cytogenetics, cytochemistry, B12)

64
Treatment
  • Substitution - vitamin B12 300 1000 µg/d
  • - maintainance dose
  • 1 x za 6 8weeks
    all life long
  • reticulocyte crisis 5.-7.d of
    treatment
  • rise of reticulocyte count up to
    10-30.
  • need of iron metabolism parameters,
    regular GSK and colonoscopy

65
  • Autoimmune disease
  • Smooth tongue surface, vitiligo, grey hair
  • Not just anaemia, but pancytopenia
  • Parenteral substitution of B12
  • Reticulocyte crisis
  • GSK á 1-2years

66
Anaemia with increased no of reticulocytes
  • HEMOLYTIC ANAEMIA
  • - corpuscular
  • - estracorspuscular
  • bleeding - acute

67
CORPUSCULAR HEMOLYTIC ANAEMIA
  • MEMBRANE DEFECTS
  • ENZYMOPATIA
  • HEMOGLOBINOPATIA

68
NON-IMMUNE ACQUIRED HEMOLYTIC ANAEMIA
  • MECHANICAL AND PHYSICAL CAUSES
  • heart valve impairement
  • hemoglobinuria
  • microangiopatic hemolytic anemia
  • widespread burns
  • METABOLIC CAUSES
  • liver disease, alcoholism
  • hypofosfatemia
  • hereditary abetalipoproteinemia
  • malnutrition
  • Cu overload
  • Wilsons disease
  • CHEMICAL SUBSTANCES
  • oxidative agents, snake venon
  • INFECTIONS

69
Corpuscular Haemolytic anaemias
  • Pathogenesis
  • Lack of and defects in membrane proteins
    (ankyrin, spectrin, etc.)
  • ?
  • Decreasesd size of ery surface spherocyte
  • increased cell membrane permeability ( Na )
  • ?
  • Increased need for eneregy -
  • - (Na pump) increased rigidity and loss of
    flexibility
  • ?
  • passge through spleen sinusoid more
    difficult ?
  • loss of membrane parts
    microspherocyte
  • cell deth in the spleen
    ?
  • EXTRAVASCULAR HAEMOLYSIS

70
Hereditary spherocytosis
  • Autosomal dominant ( rarely recesiive) disease
    with variable gene expressivity ? variable
    clinical symptoms (phenotype)
  • ( anemia with icterus, splenomegaly,
    hemolytic crisis ).
  • Diagnostics
  • Anemia s reticulocytosis spherocytes in blood
    smear, Hyperpluasti erythropoiesis in bone
    marrow, increased level of both direct and
    indirect bilirubin, serum Fe a feritin not
    increased
  • Osmotic resistance of erythrocytes decreased
  • Autohemolýza ( upravuje se po podání glukózy i
    ATP ) increased
  • PINK test
  • Dif dg. other corpuscular anemias (HE,
    etc.)
  • imunne hemolytic anemias
  • non-immune
    extracorpuscular hemolytic anemias
  • paroxysmal nocturnal
    hemoglobinuria
  • sometimes MDS
  • Lécba splenectomy

71
  • ERYTROCYTE ENZYMOPATHY
  • Defects in enzymes of anaerobe glykolysis
  • pyruvát kinázy defficiency (PKD)
    chronic
  • haemolytick anemia, with little
    effect of splnectomia
  • Defect in enzymes of pentos cycle
  • glucose-6-phosphate dehydrogenase
    defficiency
  • increased sensitivity to oxydazing
  • agents chronic haemolysis
  • or haemolytic crisis
  • anemia with Heinz
    bodies

72
ANAEROBE GLYKOLYSIS
73
GLUCOSE-6-PHOSPHATE DEHYDROGENASE defficiency
  • Results in lack of NADPH . Increased
    sensitivity to oxydating agents
  • Gene for G6PDH X chromosome , wide
    physiologic variability of the enzyme
  • Mutation mostly point mutation in 1 or to
    bases ?
  • decreased enzyme production, production
    of the enzyme with decreased
  • activity or production of the enzyme with
    decreased afinty to the substrate or
  • with decreased stability
  • Wide variability in clinical symptoms
  • Silent carrier severe
    haemolytic crisis, neonatal icterus
  • Diagnostics
  • G-6-PD activity analysis
  • Activity to substrate analysis, mobility in ELFO,
    stability
  • Molecular genetics
  • Other GSH stability test, Heinz body formation
    test
  • Th

74
(No Transcript)
75
(No Transcript)
76
HEMOGLOBINOPATHIES
  • Abnormal Hb with mostly one aminoacid (AA)
    substitution in the globion chaine
  • a/ sicle cell anemia HbS
  • b/ Hb C, Hb D, Hb E chronic haemolytic
    anemias often in combination with Hb S or ? thal
  • c/ instable haemoglobin diseases
  • hydrofobe AA ? decreased binding
    activity of Hb or impaired secondary structure of
    Hb
  • and contacts between subunits
  • chronic hemolytic anemia with Heinz
    bodies( denaturation of nestable Hb )
  • d/ methemglobinemia
  • Fe3 stabilisation due to histidine
    tyrosine in proximity of hem group
    results in cynosis
  • e/ hemoglobine with increased oxygen
    affinity
  • tissue hypoxia, cyanosis,
    polycythaemia in blood count.


77
(No Transcript)
78
SICLE CELL ANEMIA
  • Substitution glutamate valin on 6.
    position ?
  • chain Hb polymerisation, deformation of
    erythrocyte, tvaru sickle cell.
  • hemolýza extravscular intravascular (small
    vessel obstruction)
  • Autosomal dominant type
  • homozygotic form both ? chains impaired

  • heterozygotic form one ? chain impaired
  • 25-50 HbS
    sickle cell trait

79
SRPKOVITÁ ANÉMIE
  • Clinicaly
  • Hemolytic aplastic crisis, splenomegaly,
  • Diagnostics
  • krevní obraz anemie s retikulocytozou a
  • srpkovitými
    ery
  • elfo hemoglobinu prítomnost Hb S
  • identifikace Hb S peptickým štepením
    globinu
  • molekul.genetika analýza DNA -
    v prenatální péci
  • Treatment
  • Crisis prevention, transfusions, SCT

80
NEIMUNNÍ ZÍSKANÉ HEMOLYTICKÉ ANÉMIE
  • MECHANICKÉ A FYZIKÁLNÍ PRÍCINY
  • vadná srdecní chlopen
  • pochodová hemoglobinurie
  • mikroangiopatické hemolytické anémie
  • rozsáhlé popáleniny
  • METABOLICKÉ PRÍCINY
  • jaterní choroby, alkoholismus
  • hypofosfatémie
  • hereditární abetalipoproteinemie
  • podvýživa
  • nadbytek medi, Wilsonova choroba
  • CHEMICKÉ LÁTKY
  • oxidacní cinidla, hadí jedy
  • INFEKCE
  • prímá infekce erytrocytu malárie aj.

81
MIKROANGIOPATICKÁ HEMOLYTICKÁ ANÉMIE
  • prícina rozrušení integrity membrány
    erytrocytu mechanickou prícinou v prusvitu cévy,
    nejcasteji depozity fibrinu v míste poškození
    endotelu cévní steny.
  • Vaskulitidy, akutní glomerulonefritis, po
    SCT, nádory, operace chlopní, AV malformace, léky
    ticlopidin, infekce Shigatoxin.
  • fragmentace krvinek schistocyty zvýšený zánik
    ve slezine, pri masivní hemolýze
    intravaskulární hemolýza pri soucasné aktivaci
    kaogulacního systému DIC s tvorbou mikrotrombu
    v cirkulaci.
  • klinický obraz dán kombinací hemolytické
    anémie, trombocytopénie a prítomnosti mikrotrombu
    (CNS, ledviny )
  • HUS, TTP, HELLP v gravidite hemolýza,
    poruchy jaterních funkcí, trombocytopenie, DIC.

82
Patofyziologie HUS a diagnostika
toxin
aktivace endotelu
aktivace monocytu
zánik endotelií
sekrece cytokinu sekrece
vWF exprese adhezivních molekul
sekrece cytokinu
deskvamace endotelií
aktivace trombocytu
adheze a invaze neutrofilu
adheze trombocytu
trombocytopenie okluze glomerulu MAHA renální
selhání
aktivace neutrofilu
poškození endotelií
elastázy, proteázy, H2O2
83
MIKROANGIOPATICKÁ HEMOLYTICKÁ ANÉMIE
  • Laboratorní nález
  • anémie s retikulocytózou, schistocyty,
    akantocyty, sférocyty,
  • trombocytopenie se známkami DIC, nález
    multimeru pri elfo vWF pri TTP, molekulárne
    genetické vyšetrení.
  • Zvýšen prímý i neprímý bilirubin v séru,
    zvýšení LDH,
  • proteinurie, Hburie, zvýšen volný Hb,
    kreatinin, urea.
  • Lécba
  • lécba vyvolávající príciny, u TTP/HUS
    plasmaferéza se substitucí cerstvou zmrazenou
    plasmou, kortikoidy, antikoagulancia, transfuze
    erytrocytu.

84
(No Transcript)
85
AUTOIMMUNE HEMOLYTIC ANAEMIA Clasification
  • HEAT antibodies
  • - idiopatic
  • - secondary (lymfoproliferation, other
    type of tumours, autoimmune
  • diseases, viral infections,
    immunodefficiency)
  • -drug induced HA
  • COLD antibodies
  • - idiopatic
  • - secondary (lymfoproliferation, viral
    inf., mykoplasma, autoimmune diseases
  • - paroxysmal cold haemoglobinuria (lues
    )
  • MIXED HEAT AND COLD antibodies

86
Pathogenesis of AIHA
  • Cooperation disorder among supresor T helper T
    lymphocytes and B lymphocytes responsible for
    immunity control
  • Dysregulation of this system leads to
    insufficient supression of antibody formation
    against own antigens

87
IgG monomér, Fc cást vazebné místo pro C1q
složku komplementu a Fc? receptor makrofágu.
IgM pentamér, Fc cást vazebné místo pro C1q
složku komplementu a Fc? receptor makrofágu.
88
HEAT ANTIBODIES
  • IgG character optimal at 370C
  • Catch up of erythrocytes with binded antibody by
    spleen macrophages
  • EXTRAVASCULAR HEMOLYSIS
  • Activation of complement by high antibody titre
  • INTRAVACULAR HEMOLYSIS

89
COLD ANTIBODIES
  • IgM character optimál at 40C
  • Bound to erytrocytes in colder acral parts,
    possibility of complement activation, ery
    aglutination
  • INTRAVASCULAR HEMOLYSIS
  • EXTRAVASCULAR HEMOLYSIS

90
Secondary AIHA with heat antibodies
  • AUTOIMMUNE DISEASES
  • systemic lupus erytematodes, revmatoid
    arthritis,
  • sclerodermia, ulcerose colitis, syndrome of
    antiphospholipid antibodies
  • HEMATOLOGIC TUMOURS
  • chronic lymphadenosis,malign lymphomas, rarely
    acute
  • leucaemia
  • OTHER TUMOURS
  • carcinoma, thymoma, Kaposi sarkoma, teratoma
  • INFECTIONS
  • EBV, HIV-1,2, HCV, vaccination
    (difteria-pertusis-tetanus)
  • IMUNODEFICIENCY
  • congenital and acquired hypogamaglobulinemia and
  • dysgamaglobulinemia

91
DRUG-INDUCED HEMOLYTIC ANAEMIA
  • hapten type
  • imunocomplex type
  • De-novo antigen formation

92
AIHA laboratory parameters
  • Blood count
  • makrocytic anaemia with reticulocytosis
  • Biochemistry
  • ? direct and indirect bilirubin,
  • ? urobilinogen in urine
  • Special tests
  • Direct and indirect antiglobuline test (Coombs
  • test)
  • INTRAVASCULAR HEMOLYSIS PROOF
  • ? free Hb in plasma,
  • ? levels of haptoglobin and hemopexin in
    serum,
  • hemoglobinuria

93
DIRECT COOMBS TEST
We add anti IgG
Erytrocytes with bound Ab

94
INDIRECT COOMBS TEST
Sérum with free antibodies
we add erythrocytes of particular blood group
we add anti IgG or anti C3b
95
AIHA diferential diagnosis
  • CORPUSCULAR HEMOLYTIC ANAEMIA
  • negative Coombs test, positive special
    tests (autohemolysis, erytrocyte enzyme tests,
    elfo Hb, shortened lifespan of autologous, not
    donor erythrocytes) PAROXYSMÁL NIGHT
    HAEMOGLOBINURIA
  • negative Coombs test, pancytopenia, CD59
    and CD55 antigen defficiency on erythrocytes,
    CD14 antigen def. on the surface of granulocytes
    and monocytes
  • GILBERT DISEASE- negative hemolysis tests
  • NON- IMMUNE HEMOLYTIC ANAEMA
  • microangiopatic hemolytic anemia
    (schistocytes, kidney and CNS affection), anemia
    from physical and chemical causes
  • MYELODYSPLASTIC SYNDROME - hemolytic form
  • morfological dysplastic
    changes,chromosomal aberances,cytochemical
    changes, clonality.

96
AIHA - treatment
  • Light form ( Hb gt 80 g/l )
  • PREDNISONE 1 mg/kg/d 2-3 weeks
  • - in case of good effect decreasing dose
    every 2-3 days by 10mg until 20 mg/day.
  • - slow reduction of dose (by 5mg in 7-10
    days) until 5-10mg every second day.
  • - end of corticooid therapy when
    repeated direct Coombs test negativity
  • When therapy is ineffective or relaps occurs
    combination with
  • CYCLOPHOSPHAMIDE 100-150 mg/d or
  • CYCLOSPORINE A 3 mg/kg/d.

97
AIHA - treatment
  • SEVERE form ( Hb lt 80 g/l )
  • PREDNISONE 1-2 g i.v. daily 5 days, after
    that in case of good response fast decrese of
    dose to 1 mg/kg.
  • - combination of corticoids with
  • CYCLOPHOSPHAMIDE 200 mg i.v./d
  • i.v. IMMUNOGLOBULINS 0,5g /kg/d
  • PLASMAPHERESIS
  • RITUXIMAB (anti CD20 monoclonal Ab)
  • Transfusion together with corticoids ,
    monitored hospitalised patient, not more then 1
    TU/day (unless vital indication)

98
  • Thank you
Write a Comment
User Comments (0)
About PowerShow.com